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Sarcoidosis developing after
treatment with interferon alphaFigure  1  Hardened,  erythematous  zones  above  the  right
knee, with  increased  local  temperature.
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Sarcoidosis posterior a tratamiento con
interferón alfa en paciente con hepatitis C:
una asociación que todo médico debería
conocer
Sarcoidosis  is  a  chronic  granulomatous  disease  of  unknown
etiology  that  basically  affects  lung  and  adenopathic  tis-
sue,  although  it  can  involve  any  tissue.1--9 Its  diagnosis
requires  the  combination  of  clinical,  radiologic,  and  histo-
logic  ﬁndings  and  treatment  varies  according  to  its  severity.
Interferon  has  been  implicated  in  the  etiology  of  the  forma-
tion  of  granulomas  and  in  1987  the  ﬁrst  case  of  sarcoidosis
secondary  to  the  use  of  interferon  alpha  was  reported.3
Approximately  100  cases  of  sarcoidosis  related  to  the  use
of  interferon  have  been  published  in  the  literature.4,5 Inter-
feron  is  currently  a  widely  used  therapy  for  the  treatment
of  hepatitis  C.  We  present  herein  the  case  of  a  48-year-
old  woman  that  presented  with  pain  in  both  knees  of
one-month  progression.  Her  past  history  included  hepatopa-
thy  from  the  hepatitis  C  virus  treated  with  triple  therapy
(telaprevir  +  interferon  +  ribavirin),  which  ended  2  months
prior  to  symptom  onset.  Physical  examination  revealed  2
hardened,  erythematous  zones  above  the  right  knee  with
increased  local  temperature  and  no  lesions  in  the  pretib-
ial  zone  (ﬁg.  1).  The  analytic  parametric  studies  were
normal  (ANAs,  RF,  ESR,  and  CRP,  slightly  elevated  ACE)
and  the  Mantoux  test  was  negative.  Chest  x-ray  revealed
modest  perihilar  thickening.  It  was  conﬁrmed  by  tomo-
graphy  scan  that  also  identiﬁed  adenopathic  perihilar  and
mediastinic  conglomerates.  Respiratory  function  tests  were
normal.  Biopsy  of  the  nodular  lesions  reported  changes
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onsistent  with  «subcutaneous  sarcoidosis» (ﬁg.  2).  Follow-
p  and  surveillance  were  decided  upon.  The  patient  had
linical  improvement  and  symptoms  disappeared  6  months
ater.  All  diagnoses  of  sarcoidosis  within  the  last  2  years  were
eviewed  in  our  hospital  database  and  we  found  no  other
imilar  case.
There  is  a clear  relation  between  the  appearance  of
arcoidosis  and  interferon  alpha  use  and  various  cases
f  sarcoidosis  activation/reactivation  during  the  disease
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ourse  of  patients  with  hepatitis  C  virus  undergoing  said
reatment.2,4,6,9
Symptoms  can  occur  during  treatment  or  up  to  2  years
fter  its  suspension.  Nevertheless,  it  is  difﬁcult  to  know  the
ncidence  of  this  entity.1
Even  though  the  natural  history  of  sarcoidosis  is  highly
ariable,  in  one  study  of  patients  with  interferon-associated
arcoidosis,  85%  of  the  patients  were  spontaneously  cured
nd  10%  of  the  cases  became  chronic,  utilizing  corticoids
n  the  most  severe  cases.2 Other  treatments  that  have
een  used  are  hydroxychloroquine10 and  inﬂiximab.11 The
dministration  of  corticoids  can  increase  the  viral  bur-
en  and  hepatitis  C  virus  itself  induces  interferon  alpha
xpression. 12
It  is  relatively  common  in  medical  consultations  to  ﬁnd
atients  with  hepatitis  C  virus,  therefore  if  there  are  symp-
oms  that  lead  to  suspicion  of  sarcoidosis,  the  physician
ust  take  into  account  the  association  of  this  entity  with
nterferon  alpha  use.
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